Cargando…
Metabolomic, Proteomic, and Single-Cell Proteomic Analysis of Cancer Cells Treated with the KRAS(G12D) Inhibitor MRTX1133
[Image: see text] Mutations in KRAS are common drivers of human cancers and are often those with the poorest overall prognosis for patients. A recently developed compound, MRTX1133, has shown promise in inhibiting the activity of KRAS(G12D) mutant proteins, which is one of the main drivers of pancre...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Chemical Society
2023
|
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696623/ https://www.ncbi.nlm.nih.gov/pubmed/37983312 http://dx.doi.org/10.1021/acs.jproteome.3c00212 |